Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B) (AA 21-39) antibody

Details for Product No. ABIN108499
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms ocif, opg, tr1, OCIF, OPG, TR1, Opg
Epitope
AA 21-39
(8), (7), (5), (4), (4), (3), (2), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human
(98), (3), (2), (1), (1), (1)
Host
Mouse
(67), (21), (6), (4), (1)
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
(10), (3), (3), (3), (3), (3)
Application
Western Blotting (WB)
(85), (62), (40), (10), (9), (9), (8), (8), (6), (2)
Pubmed 5 references available
Quantity 0.1 mg
Shipping to United States ( )
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Immunogen
  • The antibody is a mouse monoclonal antibody against synthetic peptide of Human Osteoprotegerin. The peptide comprises AA21 to AA39 homologous with Human Osteoprotegerin (N-terminal C has been added to the peptide).
  • Source of Immunogen: Synthetic peptide
Clone OPG-13
Isotype IgG1 kappa
No Cross-Reactivity Human
Cross-Reactivity (Details) Not yet tested in other species.
Purification Affinity chromatography on a column with immobilized protein G.
Alternative Name Osteoprotegerin (TNFRSF11B Antibody Abstract)
Background
  • Osteoprotegerin (OPG) or osteoclastogenesis inhibitory factor (OCIF) is a secretory glycoprotein belonging to TNF receptor superfamily. OPG consists of 401 amino acid residues, it has a molecular weight of 60 kDa as a monomer and 120 kDa as a disulfide-linked dimer and is produced in different tissues, e.g. bone, skin, liver, stomach, intestine and lung. Osteoprotegerin inhibits the recruitment, proliferation and activation of osteoclasts. Osteoclast formation activity may be monitored principally by determination of concentration ratio of osteoprotegerin ligand (OPGL)/OPG. Alteration of this ratio may be the cause of bone loss in many imbalances in bone metabolism such as osteoporosis, osteopetrosis, hypercalcemia, metastatic osteolytic lesions and rheumatic bone degradation.
  • Other Names: OPG, Osteoclastogenesis inhibitory factor, OCIF
  • Research Areas: Bone and cartilage metabolism
Research Area Cardiovascular, Atherosclerosis, Extracellular Matrix, Innate Immunity, Cytokines
Application Notes
  • Quality control: SDS PAGE - to determine purity of the antibody
  • Otimal working dilution should be determined by the investigator.
Restrictions For Research Use only
Format Lyophilized
Reconstitution Add 0.1 mL of deionized water and let the lyophilized pellet dissolve completely. Slight turbidity may occur after reconstitution, which does not affect activity of the antibody. In this case clarify the solution by centrifugation
Buffer The antibody is lyophilized in 0.05 M phosphate buffer, 0.1 M NaCl, pH 7.2. AZIDE FREE.
Preservative Azide free
Storage 4 °C/-20 °C/-80 °C
Storage Comment The lyophilized antibody remains stable and fully active until the expiry date when stored at -20 °C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles and store frozen at -80 °C. Reconstituted antibody can be stored at 4 °C for a limited period of time, it does not show decline in activity after one week at 4 °C.
Expiry Date See label
General Kwan Tat S, Padrines M, Theoleyre S et al.: "IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology." in: Cytokine Growth Factor Rev, Vol. 15, Issue 1, pp. 49-60, 2004 (PubMed).

Kaden JJ, Bickelhaupt S, Grobholz R et al.: "Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification." in: J Mol Cell Cardiol, Vol. 36, Issue 1, pp. 57-66, 2004 (PubMed).

Skoumal M, Kolarz G, Woloszczuk W et al.: "Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis." in: Ann Rheum Dis, Vol. 63, Issue 2, pp. 216-7, 2004 (PubMed).

Yasuda, Shima, Nakagawa et al.: "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro." in: Endocrinology, Vol. 139, Issue 3, pp. 1329-37, 1998 (PubMed).

Simonet, Lacey, Dunstan et al.: "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. ..." in: Cell, Vol. 89, Issue 2, pp. 309-19, 1997 (PubMed).

Validation Images
Catalog No. ABIN108499
Contact our Customer Service for availability and price in your country.
Add to Basket

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)
Did you look for something else?